Zheng Feng
Head, Clinical Genomics, Global Clinical Biomarkers & Companion Diagnostics EMD Serono
Seminars
Wednesday 22nd July 2026
Right Test Selection, Right Clinical Setting: Aligning Fit-for-Purpose, Cost, Feasibility, & Global Deployment in Liquid Biopsies
4:15 pm
- Critical Decision-Making Matrix: Balancing clinical utilities, drug development approaches, and risk mitigation in liquid-biopsy assay selection strategy
- Define best practice for enabling liquid biopsy from clinical trials to routine clinical application: analytical performance, cost, reimbursement, tiered cut-off strategy, operations, regulatory end-to-end CDx integration, etc.
- Embracing and Taming AI: Accelerating real-world, multi-variant liquid-biopsy analytics, while recognizing that model complexity can introduce validation, regulatory, or adoption challenges and potentially diminish immediate clinical gain
Wednesday 22nd July 2026
Panel Discussion: Integrating Emerging Diagnostic Technologies to Enable Faster, More Informed Clinical Development
3:15 pm
- How to integrate emerging diagnostics, including liquid biopsy, with complimentary modalities to generate earlier, higher confidence clinical signals for Clinical Decision
- What is required to make these technologies decision-grade at scale, including validation, standardization, operational workflow, Clinical application, Global Deployment
- Where integration most accelerates development, improving patient selection, response monitoring, and resistance insight to deliver more effective therapies faster
Wednesday 22nd July 2026
Panel Discussion: Embedding Liquid Biopsy Infrastructure to De-Risk LBx/CDx Strategy & Enable Scalable Precision Medicine Execution
12:30 pm
- Align assay performance and pre-analytical validation with regulatory-grade CDx requirements to ensure sample integrity, analytical robustness and global approval confidence
- Standardize collection, handling and laboratory workflows across trial networks to reduce variability, protect data quality and enable reproducible, scalable execution
- Integrate translational biomarker strategy with operational laboratory oversight to bridge early molecular insight with decision-grade, clinically deployable implementation
